"The selection of Vigodman is credit positive as it reduces the risk that there will be a significant departure from Teva's previously-stated strategy."
Moody's Investors Service has characterized the appointment of Erez Vigodman as CEO of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) as "credit positive".
"The selection of Vigodman -- who has been on Teva's board of directors since 2009 -- is credit positive as it reduces the risk that there will be a significant departure from Teva's previously-stated strategy," Moody's said, adding, "There is no change to Teva's A3 rating or the negative outlook."
Published by Globes [online], Israel business news - www.globes-online.com - on January 9, 2014
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013